MA70825B1 - Traitement de douleur associée à la sensibilisation centrale - Google Patents

Traitement de douleur associée à la sensibilisation centrale

Info

Publication number
MA70825B1
MA70825B1 MA70825A MA70825A MA70825B1 MA 70825 B1 MA70825 B1 MA 70825B1 MA 70825 A MA70825 A MA 70825A MA 70825 A MA70825 A MA 70825A MA 70825 B1 MA70825 B1 MA 70825B1
Authority
MA
Morocco
Prior art keywords
pain associated
treating pain
central sensitization
sensitization
central
Prior art date
Application number
MA70825A
Other languages
English (en)
Inventor
Basil Rigas
Original Assignee
Medicon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicon Pharmaceuticals, Inc. filed Critical Medicon Pharmaceuticals, Inc.
Publication of MA70825B1 publication Critical patent/MA70825B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention features methods of treating pain, for example pain associated with central sensitization, with phosphosulindac and compositions thereof.
MA70825A 2022-11-23 2023-11-21 Traitement de douleur associée à la sensibilisation centrale MA70825B1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263384795P 2022-11-23 2022-11-23
US202263384793P 2022-11-23 2022-11-23
US202263384796P 2022-11-23 2022-11-23
US202263384794P 2022-11-23 2022-11-23
US202263384792P 2022-11-23 2022-11-23
US202263384790P 2022-11-23 2022-11-23
US202363483353P 2023-02-06 2023-02-06
PCT/US2023/080646 WO2024112725A1 (fr) 2022-11-23 2023-11-21 Traitement de douleur associée à la sensibilisation centrale
EP23837005.0A EP4522143B1 (fr) 2022-11-23 2023-11-21 Traitement de douleur associée à la sensibilisation centrale

Publications (1)

Publication Number Publication Date
MA70825B1 true MA70825B1 (fr) 2025-12-31

Family

ID=89378489

Family Applications (1)

Application Number Title Priority Date Filing Date
MA70825A MA70825B1 (fr) 2022-11-23 2023-11-21 Traitement de douleur associée à la sensibilisation centrale

Country Status (16)

Country Link
US (1) US20250345350A1 (fr)
EP (3) EP4622638A1 (fr)
JP (2) JP2025541616A (fr)
KR (2) KR20250121336A (fr)
CN (2) CN120603589A (fr)
AU (2) AU2023385702A1 (fr)
ES (1) ES3036667T3 (fr)
HR (1) HRP20251034T1 (fr)
HU (1) HUE072771T2 (fr)
MA (1) MA70825B1 (fr)
MD (1) MD4522143T2 (fr)
MX (2) MX2025005910A (fr)
PL (1) PL4522143T3 (fr)
RS (1) RS67089B1 (fr)
SM (1) SMT202500296T1 (fr)
WO (2) WO2024112727A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025111079A1 (fr) 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Isomères de phosphosulindac

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
ITMI20051107A1 (it) * 2005-06-14 2005-09-13 Ctg Pharma S R L Metodo per il trattamento del cancro
WO2009023631A1 (fr) 2007-08-10 2009-02-19 Basil Rigas Composés anti-inflammatoires et leurs utilisations
WO2013130625A1 (fr) 2012-02-27 2013-09-06 Basil Rigas Dérivés de phospho-ester et leurs utilisations
CA2885740A1 (fr) 2012-09-21 2014-03-27 Basil Rigas Composes et compositions pour une utilisation dans la prevention et le traitement de troubles associes a l'inflammation, de la douleur et de la fievre, de troubles de la peau, ducancer et d'etats precancereux de celui-ci
CN107614061A (zh) * 2014-12-01 2018-01-19 阿科莱尔斯疗法公司 用于治疗与疼痛有关的偏头痛和病症方法和组合物
CA3077033A1 (fr) 2017-09-28 2019-04-04 Medicon Pharmaceuticals, Inc. Compositions et methodes de traitement de troubles ophtalmiques
PL4114403T3 (pl) 2021-05-24 2023-10-09 Medicon Pharmaceuticals, Inc. Leczenie bólu neuropatycznego towarzyszącego neuropatii obwodowej indukowanej przez chemioterapię
RS64402B1 (sr) 2021-05-24 2023-08-31 Medicon Pharmaceuticals Inc Lečenje bola povezanog sa dijabetičkom perifernom neuropatijom

Also Published As

Publication number Publication date
SMT202500296T1 (it) 2025-09-12
EP4622638A1 (fr) 2025-10-01
MX2025005910A (es) 2025-09-02
JP2025541617A (ja) 2025-12-22
EP4522143B1 (fr) 2025-07-02
HUE072771T2 (hu) 2025-12-28
KR20250123139A (ko) 2025-08-14
AU2023385700A1 (en) 2025-07-10
EP4603145A3 (fr) 2025-11-19
EP4522143C0 (fr) 2025-07-02
PL4522143T3 (pl) 2025-10-13
US20250345350A1 (en) 2025-11-13
KR20250121336A (ko) 2025-08-12
WO2024112725A1 (fr) 2024-05-30
RS67089B1 (sr) 2025-09-30
HRP20251034T1 (hr) 2025-10-24
WO2024112727A1 (fr) 2024-05-30
MX2025005914A (es) 2025-09-02
CN120603589A (zh) 2025-09-05
CN120569194A (zh) 2025-08-29
JP2025541616A (ja) 2025-12-22
EP4522143A1 (fr) 2025-03-19
MD4522143T2 (ro) 2025-11-30
EP4603145A2 (fr) 2025-08-20
ES3036667T3 (en) 2025-09-23
AU2023385702A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
BR112021022504A2 (pt) Inibidores de autofagia de fenilaminopirimidina amida e métodos de uso dos mesmos
SA520420801B1 (ar) أil جسام مضادة لـ -11
PH12023500015A1 (en) Irak degraders and uses thereof
BR112021025544A2 (pt) Inibidores de autofagia de aminopirimidina amida e métodos de uso dos mesmos
MX2023013912A (es) Metodos para inhibir ras.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
MX2023014154A (es) Anticuerpos anti-ccr8.
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
GEAP202316332A (en) Cdk2 inhibitors and methods of using the same
NI202000085A (es) Moduladores de la expresión de apol1
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2021013602A (es) Inhibidores de jak.
MX2019010060A (es) Composiciones y metodo para tratar cancer.
MX2023012672A (es) Nuevo anticuerpo anti-vista estable.
MX2023002851A (es) Tratamiento de la enfermedad de parkinson.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
CO2025016192A2 (es) Moléculas y métodos de uso de estas
EP4603145A3 (fr) Traitement de la douleur associée à la sensibilisation centrale
BR112021019448A2 (pt) Métodos para o tratamento de beta-talassemia